First Zika Diagnostic Test Accepted by WHO
News Aug 22, 2016
RealStar® Zika Virus RT-PCR Kit 1.0 was listed by WHO as first in vitro diagnostic test eligible for procurement agencies and Member States. It was assessed under the Emergency Use Assessment and Listing Procedure (EUAL) - an emergency quality assessment mechanism established by WHO during the 2014 Ebola Virus Disease outbreak.
The EUAL procedure was developed to expedite the availability of IVDs needed in public health emergency situations. Such a Public Health Emergency of International Concern has been declared by WHO´s Director General on February 1st 2016. altona Diagnostics´ RealStar® Zika Virus RT-PCR Kit 1.0 allows the qualitative detection of Zika virus specific RNA in human serum or urine after extraction of the viral RNA using QIAGEN´s QIAamp Viral RNA Mini Kit. It was developed and validated for a range of real-time PCR instruments.
The test performance was validated by the Institute Pasteur de la Guyane, Cayenne, French Guiana, and the limit of detection studies have been performed at the Bernhard-Nocht-Institute for Tropical Medicine (BNITM), a WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research.
Patients in a new Northwestern Medicine study were able to comprehend words that were written but not said aloud. They could write the names of things they saw but not verbalize them. This provides an insight into the brain degeneration that defines the rare dementia termed primary progressive aphasia.
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE